The diabetic foot

Clinics in Dermatology

Volumn 25, Issue 1, 2007, Pages 109-120

  Rathur, Haris M ^a   Boulton, Andrew J M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BECAPLERMIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; LINEZOLID; PAMIDRONIC ACID; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIMICROBIAL THERAPY; ARTICLE; DEBRIDEMENT; DEVICE; DIABETIC FOOT; DIABETIC NEUROPATHY; FOOT ULCER; HUMAN; INFECTION; NEUROPATHIC JOINT DISEASE; PATHOGENESIS; PATIENT COMPLIANCE; PLASTER CAST; PRIORITY JOURNAL; SHOE; SKIN GRAFT;

DIABETIC FOOT; HUMANS; WOUND HEALING;

EID: 33846561514     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.09.015     Document Type: Article

References (120)

1. Wild S., Roglie G., Green A., and King H. Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Singh N., Armstrong D.G., and Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA 293 (2005) 217-228
3. Boyko E.J., Ahroni J.H., Smith D.G., and Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med 13 (1996) 967-972
4. Krentz A.J., Acheson P., Basu A., Kilvert A., Wright A.D., and Natrass M. Morbidity and mortality associated with diabetic foot disease: a 12-month prospective survey of hospital admissions in a single UK centre. Foot 7 (1997) 144-147
5. Jude E.B., and Boulton A.J.M. End stage complications of diabetic neuropathy. Diabetes Rev 7 (1999) 395-410
6. Abbott C.A., Carrington A.L., Ashe H., et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 20 (2002) 377-384
7. Shaw J.E., and Zimmet P.Z. The epidemiology of diabetic neuropathy. Diabetes Rev 6 (1999) 245-252
8. Williams D.R.R., and Airey M. The size of the problem: epidemiological and economical aspects of the diabetic foot. In: Boulton A.J.M., Connor H., and Cavanagh P.R. (Eds). The foot in diabetes. 3rd ed. (2000), Wiley, Chichester 3-17
9. Reiber G.E., and Ledoux W.R. Epidemiology of diabetic foot ulcers and amputations: evidence for prevention. In: Williams R., Herman W., Kinmonth A.L., and Wareham N.J. (Eds). The evidence base for diabetes care (2002), Wiley, Chichester 641-665
10. Carrington A.L., Abbott C.A., Griffiths J., Jackson N., van Ross E.R.E., and Boulton A.J.M. A foot care programme for diabetic unilateral amputees. Diabetes Care 24 (2001) 216-221
11. Kumar S., Ashe H., Fernando D.J.S., Tsigos C., Young R.J., and Boulton A.J.M. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med 11 (1994) 480-484
12. Muller I.S., de Graum W.J., van Gerwen W.H., et al. Foot ulceration and lower limb amputation in type 2 diabetic patients in Dutch primary health care. Diabetes Care 25 (2002) 570-574
13. Lavery L.A., Armstrong D.G., Wunderlich R.P., Tredwell J., and Boulton A.J.M. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes management cohort. Diabetes Care 26 (2003) 1435-1438
14. Humphrey A.R.G., Thomas K., Dowse G.K., and Zimmet P.Z. Diabetes and non-traumatic lower extremity amputations. Incidence, risk factors and prevention: a 12 year follow-up study in Nauru. Diabetes Care 19 (1996) 710-716
15. Belhadj M.A. La pace du pied diabetique. [in French]. Diabete Metab 24 Suppl (1998) LXVII
16. Pendsey S. Epidemiological aspects of the diabetic foot. Int J Diab Dev Countries 2 (1994) 37-38
17. Young M.A., Veves A., Breddy J.L., and Boulton A.J.M. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 17 (1994) 557-560
18. Abbott C.A., Vileikyte L., Williamson S., Carrington A.L., and Boulton A.J.M. Multicentre study of the incidence of and predictive factors for diabetic neuropathic foot ulcers. Diabetes Care 21 (1998) 1071-1075
19. Larsson J., Apelqvist J., Agardh G.D., and Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach?. Diabet Med 12 (1995) 770-776
20. van Houtum W.H., Rauwerda J.A., Ruwaard D., Schaper N.C., and Bakker K. Reduction in diabetes-related lower-extremity amputations in the Netherlands: 1991-2000. Diabetes Care 27 (2004) 1042-1046
21. Trautner C., Haastert B., Spraul M., Giani C., and Berger M. Unchanged incidence of lower limb amputations in a German city 1990-1998. Diabetes Care 24 (2001) 855-859
22. Trautner C., Haastert B., Giani C., and Berger M. Amputations and diabetes: a case control study. Diabet Med 19 (2002) 35-40
23. An audit of amputations in a rural health district. Pract Diabetes Int 14 (1997) 174-178
24. Oyibo S.O., Jude E.B., Voyatzoglou D., and Boulton A.J.M. Clinical characteristics of patients with diabetic foot problems: changing patterns of foot ulcer presentation. Pract Diabetes Int 19 (2002) 10-12
25. Toledano H., Young M.J., Veves A., and Boulton A.J.M. Why do Asian diabetic patients have fewer foot ulcers than Caucasians?. Diabet Med Suppl 1 (1993) 539
26. Chaturvedi N., Abbot C.A., Whalley A., Leggetter S.Y., and Boulton A.J.M. Risk of diabetes-related amputation in south Asians vs. Europeans in the UK. Diabet Med 19 (2002) 99-106
27. Leggetter S.Y., Chaturvedi N., Fuller J.H., and Edmonds M.E. Ethnicity and risk of diabetes-related lower extremity amputation: a population-based, case-control study of Afro-Caribbeans and Europeans in the United Kingdom. Arch Int Med 162 (2001) 73-78
28. Resnick H.E., Valsania P., and Phillips C.L. Diabetes mellitus and non-traumatic lower extremity in black and white Americans: the National Health and Nutrition Examination Survey Epidemiology Follow-Up Study 1971-1992. Arch Int Med 159 (1999) 2470-2475
29. Most R.S., and Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 6 (1983) 87-91
30. American Diabetes Association. Consensus development conference on diabetic wound care. Diabetes Care 22 (1999) 1354-1360
31. Shearer A., Schuffham P., Gordois A., and Ogleshy A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care 26 (2003) 2305-2310
32. Ragnarson-Tennvall G., and Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost utility analysis based on Markov model simulation. Diabetologia 44 (2001) 2077-2087
33. Assal J.P., Mehnert H., Tritschler H.S., Sidorenko A., and Keen H. 'On your feet' workshop on the diabetic foot. J Diabet Comp 16 (2002) 183-194
34. Ramsey S.D., Newton K., Blough D., et al. Incidence outcomes and costs of foot ulcers in patients with diabetes. Diabetes Care 22 (1999) 382-387
35. Diabetes care and research in Europe: the St Vincent Declaration. Diabet Med 7 (1990) 360
36. Larssen J. Lower extremity amputations in diabetic patients. Doctoral thesis, Lund University, 1994.
37. Boulton A.J.M. The pathway to ulceration: aetiopathogenesis. In: Boulton A.J.M., Connor H., and Cavanagh P.R. (Eds). The foot in diabetes. 3rd ed. (2000), Wiley, Chichester 19-31
38. Reiber G.E., Vileikyte L., Boyko E.J., et al. Causal pathway for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care 22 (1999) 157-162
39. Boulton A.J.M., Hardisty C.A., Betts R.P., et al. Dynamic foot pressure and other studies as diagnostic and management aids for diabetic neuropathy. Diabetes Care 6 (1983) 26-33
40. Katoulis E.C., Ebdon-Parry M., Hollis S., et al. Postural instability in diabetic patients at risk of foot ulceration. Diabet Med 14 (1997) 296-300
41. Katoulis E.C., Ebdon-Parry M., Lanshammer H., et al. Gait abnormalities in diabetic neuropathy. Diabetes Care 20 (1997) 1904-1907
42. Vileikyte L., Rubin R.R., and Leventhal H. Psychological aspects of diabetic neuropathy and its late sequelae. Diabetes Metab Res Rev 20 Suppl 1 (2004) S13-S18
43. Young M.J., Boulton A.J.M., MacCleod A.F., Williams D.R.R., and Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population. Diabetologia 36 (1993) 150-154
44. Mayfield J.A., and Sugarman J.R. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulcerations and amputations in persons with diabetes. J Fam Pract 49 Suppl 11 (2000) S17-S29
45. Booth J., and Young M.J. Differences in the performance of commercially available monofilaments. Diabetes Care 23 (2000) 984-988
46. Miranda-Palma B., Basu S., Mizel M.S., et al. The monofilament as gold standard for foot ulcer risk screening: a reappraisal. Diabetes 53 Suppl 1 (2003) A63
47. Carrington A.L., Shaw J.E., Van Schie C.H.M., Abbott C.A., Vileikyte L., and Boulton A.J.M. Can motor nerve conduction velocity predict foot problems in diabetes over a six year outcome period?. Diabetes Care 25 (2002) 2010-2015
48. National Diabetes Advisory Board. The prevention and treatment of five complications of diabetes: a guide for primary care practitioners (1983), Centers for Disease Control, Atlanta (GA) HHS publ. no. 83-8392
49. Jude E.B., Oyibo S.O., Chalmers N., and Boulton A.J.M. Peripheral arterial disease in diabetic and non-diabetic patients: a comparison of severity and outcome. Diabetes Care 24 (2001) 1433-1437
50. Lavery L.A., Armstrong D.G., Vela S.A., et al. Practical criteria for screening patients at high risk of diabetic foot ulceration. Arch Int Med 26 (1998) 157-162
51. Murray H.J., Young M.J., and Boulton A.J.M. The relationship between callus formation, high pressures and neuropathy in diabetic foot ulceration. Diabet Med 13 (1996) 979-982
52. Valk G.D., Kreigsman D.M., and Assendelf W.J. Patient education for reducing diabetic foot ulceration: a systematic review. Endocrinol Metab Clin N Am 31 (2002) 633-658
53. McCabe C.J., Stevenson R.C., and Dolan A.M. Evaluation of a diabetic foot screening and prevention programme. Diabet Med 15 (1998) 80-84
54. Vileikyte L. Psychological and behavioural issues in diabetic neuropathic foot ulceration. In: Boulton A.J.M., Connor H., and Cavanagh P.R. (Eds). The foot in diabetes. 3rd ed. (2000), Wiley, Chichester 121-130
55. Harris M.I., Eastman R., and Cowle C. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 16 (1993) 1446-1452
56. Van R., Deursen W., Sanchez M.M., Ulbrecht J.S., and Cavanagh P.R. The role of muscle spindles in ankle movement perception in human subjects with diabetic neuropathy. Exp Brain Res 120 (1998) 1-8
57. Cavanagh P.R., Simoneau G.G., and Ulbrecht J.S. Ulceration, unsteadiness and uncertainty: the biomechanical consequences of diabetes mellitus. J Biomech 26 Suppl 1 (1993) 23-46
58. Boulton A.J.M., Gries F.A., and Jervell J.A. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15 (1998) 508-514
59. Dyck P.J., Kratz K.M., Karnes J.L., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43 (1993) 817-824
60. Eaton S., and Tesfaye S. Clinical manifestation and measurement of neuropathy. Diabetes Rev 7 (1999) 312-325
61. Mayfield J.A., Reiber G.E., Sanders L.J., Janisse D., and Pogach L.M. Preventive foot care in people with diabetes. Diabetes Care 21 (1998) 2161-2177
62. Cavanagh P.R., Young M.J., Adams J.E., Vickers K.L., and Boulton A.J.M. Radiographic abnormalities in the feet of patients with diabetic neuropathy. Diabetes Care 17 (1994) 201-209
63. Brower A.C., and Allman R.M. Pathogenesis of the neurotrophic joint: neurotraumatic vs. neurovascular. Radiology 139 (1981) 349-354
64. Edmonds M.E., Clarke M.B., Newton S., Barrett J., and Watkins P.J. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 57 (1985) 843-855
65. Young M.J., Marshall A., Adams J.E., Selby P.L., and Boulton A.J. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 18 (1995) 34-38
66. Schon L.C., Easley M.E., and Weinfeld S.B. Charcot neuroarthropathy of the foot and ankle. Clin Orthop 349 (1998) 116-131
67. Jude E.B., Selby P.L., Burgess J., et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double blind randomized controlled trial. Diabetologia 44 (2001) 2032-2037
68. Delamaire M., Maugendre D., Moreno M., Le Goff M.C., Allannic H., and Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 14 (1997) 29-34
69. Young B.A., Maynard C., Reiber G.E., and Boyko E.J. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care 26 (2003) 495-501
70. Sorensen L.T., Karlsmark T., and Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Ann Surg 238 (2003) 1-5
71. Hess C.T., and Kirsner R.S. Orchestrating wound healing: assessing and preparing the wound bed. Adv Skin Wound Care 16 (2003) 246-259
72. Zacur H., and Kirsner R.S. Debridement: rationale and therapeutic options. Wounds 14 Suppl E (2002) 2E-7E
73. Steed D.L., Donohoe D., Webster M.W., and Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 183 (1996) 61-64
74. Armstrong D.G., and Nguyen H.C. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 135 (2000) 1405-1409
75. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. Diabetes Care 22 (1999) 1354-1360
76. Mueller M.J., Diamond J.E., Sinacore D.R., et al. Total contact casting in treatment of diabetic plantar ulcers: controlled clinical trial. Diabetes Care 12 (1989) 384-388
77. Armstrong D.G., Nguyen H.C., Lavery L.A., van Schie C.H., Boulton A.J.M., and Harkless L.B. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 24 (2001) 1019-1022 [Erratum, Diabetes Care 2001;24:1509]
78. Armstrong D.G., Lavery L.A., Kimbriel H.R., Nixon B.P., and Boulton A.J.M. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care 26 (2003) 2595-2597
79. Piaggesi A., Viacava P., Rizzo L., et al. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief. Diabetes Care 26 (2003) 3123-3128
80. Armstrong D.G., Short B., Espensen E.H., Abu-Rumman P.L., Nixon B.P., and Boulton A.J. Technique for fabrication of an "instant total-contact cast" for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 92 (2002) 405-408
81. Williams D.T., and Harding K.G. New treatments for diabetic neuropathic foot ulceration: views from a wound healing unit. Curr Diabetes Rep 3 (2003) 468-474
82. Mason J., O'Keefe C.O., Hutchinson A., McIntosh A., Young R.J., and Booth A. A systematic review of foot ulcers in patients with type 2 diabetes mellitus. II. Treatment. Diabet Med 16 (1999) 889-909
83. Veves A., Sheehan P., and Pham H.T. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 137 (2002) 822-827
84. Lipsky B.A., and Berendt A.R. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 16 Suppl 1 (2000) S42-S46
85. Lipsky B.A. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20 Suppl 1 (2004) S68-S77
86. Chantelau E., Tunudjaja T., Altenhofer F., Ersanli Z., Lacigova S., and Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 13 (1996) 156-159
87. Lipsky B.A., Itani K., and Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38 (2004) 17-24
88. Wieman T.J., Smiell J.M., and Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 21 (1998) 822-827
89. Bennett S.P., Griffiths G.D., Schor A.M., Leese C.P., and Schor S.L. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 90 (2003) 133-146
90. Kirsner R.S., Falanga V., and Eaglstein W.H. The development of bioengineered skin. Trends Biotechnol 16 (1998) 246-249
91. Veves A., Falanga V., Armstrong D.G., and Sabolinski M.L. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24 (2001) 290-295
92. Marston W.A., Hanft J., Norwood P., and Pollak R. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26 (2003) 1701-1705
93. Veves A., and Boulton A.J.M. The optical pedobarograph. Clin Podiatr Med Surg 10 (1993) 463-470
94. Boulton A.J.M., Betts R.P., Franks C.I., et al. Abnormalities of foot pressure in early diabetic neuropathy. Diabet Med 4 (1987) 225-228
95. Boulton A.J.M., Betts R.P., Franks C.I., Ward J.D., and Duckworth T. The natural history of foot pressure abnormalities in neuropathic diabetic subjects. Diabetes Res 5 (1987) 73-77
96. Newrick P.G., Cochrane T., Betts R.P., Ward J.D., and Boulton A.J.M. Reduced hyperaemic response under the neuropathic diabetic foot. Diabet Med 5 (1988) 570-573
97. Young M.J., Cavanagh P.R., Thomas G., et al. The effect of callus removal on dynamic plantar foot pressures in diabetic patients. Diabet Med 9 (1992) 55-57
98. Veves A., Young M.J., Murray H.J., and Boulton A.J.M. The risk of foot ulceration in diabetic patients with high foot pressures: a prospective study. Diabetologia 35 (1993) 660-663
99. Lavery L.A., Armstrong D.G., Wunderlich R.P., Tredwell J., and Boulton A.J.M. Predictive value of foot pressure assessment when part of a population based diabetes disease management programme. Diabetes Care 26 (2003) 1069-1073
100. Jeffcoate W.J., and Harding K.G. Diabetic foot ulcers. Lancet 361 (2003) 1545-1551
101. Jude E.B., Blakytny R., Bulmer J., Boulton A.J.M., and Ferguson M.W.J. Transforming growth factor-beta 1, 2, 3 and receptor type 1 and 2 in diabetic foot ulcers. Diabet Med 19 (2002) 440-447
102. Lobmann R., Ambrosch A., Schultz G., et al. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 45 (2002) 1011-1016
103. Boulton A.J.M., and Armstrong D.G. Studies in planter diabetic neuropathic ulcers; time for a paradigm shift?. Diabetes Care 26 (2003) 2689-2690
104. Brand P.W. The diabetic foot. In: Ellenberg M., and Rifkin H. (Eds). Diabetes mellitus: theory and practice. 3rd ed. (1983), Med Exam Publishing, New York 829-849
105. Boulton A.J.M. Lawrence Lecture: the diabetic foot: neuropathic in aetiology?. Diabet Med 7 (1990) 852-858
106. Armstrong D.G., and Stacpoole-Shea S. TCC and removable cast walker. Mitigation of plantar heel pressure. J Am Podiatr Med Assoc 89 (1999) 50-53
107. Boulton A.J.M., Bowker J.H., Gadia M., et al. Use of plaster casts in the management of diabetic neuropathic foot ulcers. Diabetes Care 9 (1986) 149-152
108. Mueller M.J., Diamond J.E., Sinacore D.R., et al. Total contact casting in the treatment of diabetic plantar ulcers: controlled clinical trial. Diabetes Care 12 (1989) 384-388
109. Lavery L.A., Vela S.A., Lavery D.C., and Quebedeaux T.L. Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations: a comparison of treatments. Diabetes Care 19 (1996) 818-821
110. Baumhauer J.F., Wervery R., McWilliams J., Harris G.F., and Shereff M.J. A comparison study of plantar foot pressure in a standardized shoe, total contact cast prefabricated pneumatic walking brace. Foot Ankle Int 18 (1997) 26-33
111. Armstrong D.G., Lavery L.A., Wu S., and Boulton A.J.M. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomised controlled trial. Diabetes Care 28 (2005) 551-554
112. Veves A., Sheehan P., and Pham H.T. A randomized control trial of Promogran vs standard treatment in the management of diabetic foot ulcers. Arch Surg 137 (2002) 822-827
113. Ha Van G., Siney H., Hartmann-Heurtier A., Jacqueminet S., Greau F., and Grimaldi A. Nonremovable, windowed, fibreglass cast boot in the treatment of diabetic planter ulcers: efficacy, safety and compliance. Diabetes Care 26 (2003) 2848-2852
114. Spencer S. Pressure relieving interventions for preventing and treating diabetic foot ulcers (Cochrane Review). The Cochrane Library (2002), John Wiley and Sons Ltd, Chichester
115. Katz I., Harlan A., Miranda-Palma B., et al. A randomised trial of two irremovable offloading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care 28 (2005) 555-559
116. Knowles E.A., Armstrong D.G., Hayat S.A., Boulton A.J.M., et al. Offloading diabetic foot wounds using the Scotchcast boot: a retrospective study. Ostomy Wound Manage 48 (2002) 50-53
117. Macfarlane R.M., and Jeffcoate W.J. Factors contributing to the presentation of diabetic foot ulcers. Diabet Med 14 (1997) 867-870
118. Uccioli L., Faglia E., Monticone G., et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 18 (1995) 1376-1378
119. Reiber G.E., Smith D.G., Wallace C., et al. Effect of therapeutic footwear on foot reulceration in patients with diabetes: a randomized controlled trial. JAMA 287 (2002) 2552-2558
120. McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 2000;46:28-32, 34.